US Brand Name(s): Prolia, Xgeva

Use in Cancer Treatment

Denosumab is to treat the following conditions:

  • Bone tumor with a giant cell tumour that cannot be removed surgically. It is also for adults and adolescents whose bones have reached the end of their growth.
  • Malignancy-related hypercalcemia that has become worse following bisphosphonate therapy

The Xgeva brand of denosumab has the authorization for these applications.

Denosumab has approval for the following uses:

  • Multiple myeloma and solid cancers that have metastasized (spread) to bone can cause broken bones and other bone issues. The Xgeva brand of denosumab has the authorization for this purpose.

Denosumab has also the authorization for increasing bone mass in people who are at a high risk of fracturing a bone. It helps to treat the following cancers:

  • Breast cancer in women who are taking an aromatase inhibitor.
  • Men on androgen deprivation therapy develop prostate cancer.
  • The Prolia brand of denosumab has authorization for these purposes.

Denosumab is also under research for the treatment of various cancers and diseases.

Definition from the NCI Drug Dictionary – Detailed scientific definition

Denosumab Information on MedlinePlus

A summary of key information regarding this medication in layman’s terms, which may contain the following:

  • Cautions about this medicine
  • What is the use and how?
  • Whom should you consult before taking it?
  • What you should know before using it?
  • Other drugs that might interact with it
  • Possible negative side effects

Drugs are frequently under research to see whether they can assist treat or prevent conditions other than those already prevalent. This patient information leaflet covers uses which have been under authorization. Much of the material, though, might also apply to authorized uses that are being investigated.